Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
Term:	L5 same bacteri\$
Display: Generate:	Documents in Display Format: Starting with Number 1 C Hit List © Hit Count C Side by Side C Image
	Search Clear Interrupt
	Search History

DATE: Tuesday, October 12, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,	USPT, USOC, EPAB, JPAB, DWPI; PLUR = Y	YES; OP=ADJ	
<u>L6</u>	L5 same bacteri\$	81	<u>L6</u>
<u>L5</u>	sialyltransferase	827	<u>L5</u>
<u>L4</u>	L2 and bacter\$. 8	<u>L4</u>
<u>L3</u>	L2 same jejuni	1	<u>L3</u>
<u>L2</u>	alpha 2,3-sialyltransferase	25	<u>L2</u>
<u>L1</u>	alpha 2,3-sialyltranasferase	0	<u>L1</u>

END OF SEARCH HISTORY

f

rst Hit

Previous Doc

Next Doc

Go to Doc#

Generate Collection

Print

L6: Entry 48 of 81

File: PGPB

Mar 21, 2002

DCUMENT-IDENTIFIER: US 20020034805 A1

ITLE: FUSION PROTEINS FOR USE IN ENZYMATIC SYNTHYESIS OF OLIGOSACCHARIDES

ctail Description Paragraph:

0071] <u>Sialyltransferases</u> from prokaryotes have been described by, for example, Weisgerber et 1. (1991) Glycobiol. 1:357-365; Frosch, M. et al. (1991) Mol. Microbiol. 5:1251-1263; and albert, M. et al. (1996) J. Biol. Chem. 271:28271-28276. It has been suggested that the acterial sialyltransferases might have a wider spectrum of acceptors than their mammalian ounterparts (Kajihara, Y. et al. (1996) J. Org. Chem. 61:8632-8635 and Gilbert et al., Eur. iochem. 249: 187-194-(1997)).

etail Description Paragraph:

0088] The invention also provides fusion polypeptides that are useful for sialylation eactions. These fusion polypeptides include a catalytic domain from a <u>sialyltransferase</u> and atalytic domain from a CMP-sialic acid synthetase (EC 2.7.7.43, CMP-N-acetylneuraminic acid ynthetase). Such genes are available from, for example, Mus musculus (GenBank AJ006215, unster et al., Proc. Natl. Acad. Sci. U.S.A. 95: 9140-9145 (1998)), rat (Rodriguez-Aparicio 1. (1992) J Biol. Chem. 267: 9257-63), Haemophilus ducreyi (Tullius et al. (1996) J. Biol. hem. 271: 15373-80), Neisseria meningitidis (Ganguli et al. (1994) J. <u>Bacteriol</u>. 176: 4583-9 roup B streptococci (Haft et al. (1994) J. <u>Bacteriol</u>. 176: 7372-4), and E. coli (GenBank 05023, Zapata et al. (1989) J. Biol. Chem. 264: 14769-14774). Alternatively, fusion proteins or sialylation reactions can have a catalytic domain from either or both of GlcNAc 2' pimerase (EC 5.1.3.8), which converts GlcNAc to ManNAc, and neuraminic acid aldolase (EC .1.3.3; SwissProt Accession No. P06995), which in turn converts the ManNAc to sialic acid.

Previous Doc Next Doc Go to Doc#

Print Selection

Select All Clear Cancel Print Print First Page								
	Section: Page(s): Print Copy: 1							
Select?	Document ID	Section(s)	Page(s)	# Pages to print	Database			
V	6709834	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
[Z	6689604	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
V	6503744	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
Image: section of the	6699705	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
	6399336	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
V	6096529	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
V	5962294	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
V	5908766	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
	6255094	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
	5827714	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			
হ	US6255094B	all	all	N/A	PGPB,USPT,USOC,EPAB,JPAB,DWPI			

Building	Room	Printer	
rem 🔻	02c18 💌	gbumptr 💆	

L1

L2

L3

(FILE 'HOME' ENTERED AT 13:51:26 ON 12 OCT 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 14:00:32 ON 12 OCT 2004 SEA ALPHA 2,3-SIALYLTRANSFERASE

```
_____
     FILE ADISCTI
     FILE AGRICOLA
 1
     FILE ANABSTR
 3
     FILE BIOBUSINESS
     FILE BIOCOMMERCE
 1
      FILE BIOENG
15
      FILE BIOSIS
223
      FILE BIOTECHNO
160
      FILE CABA
15
      FILE CANCERLIT
98
      FILE CAPLUS
327
     FILE CEABA-VTB
 8 .
      FILE CIN
 1
      FILE DISSABS
 19
      FILE EMBAL
  1
      FILE EMBASE
209
      FILE ESBIOBASE
142
      FILE FEDRIP
 1
      FILE FROSTI
  2
      FILE FSTA
 1
      FILE GENBANK
383
      FILE IFIPAT
58
      FILE JICST-EPLUS
14
      FILE LIFESCI
102
      FILE MEDLINE
266
      FILE PASCAL
110
      FILE PROMT
  1
      FILE SCISEARCH
320
      FILE TOXCENTER
 75
      FILE USPATFULL
262
      FILE USPAT2
      FILE WPIDS
 27
      FILE WPINDEX
 27
```

FILE 'CAPLUS, SCISEARCH, MEDLINE, USPATFULL, BIOSIS, EMBASE, BIOTECHNO, ESBIOBASE, PASCAL, LIFESCI, CANCERLIT' ENTERED AT 14:04:01 ON 12 OCT 2004

47 S L1 AND JEJUNI

37 DUP REM L2 (10 DUPLICATES REMOVED)

QUE ALPHA 2,3-SIALYLTRANSFERASE

ANSWER 1 OF 37 USPATFULL on STN DUPLICATE 1 2004:33951 USPATFULL ACCESSION NUMBER: Lipopolysaccharide .alpha.-2, TITLE: 3 sialyltransferase of Campylobacter jejuni and its uses Gilbert, Michel, Hull, CANADA INVENTOR(S): Wakarchuk, Warren W., Gloucester, CANADA National Research Council of Canada, Ottawa, CANADA PATENT ASSIGNEE(S): (non-U.S. corporation) KIND DATE NUMBER _____ PATENT INFORMATION: US 6689604 B1 20040210 APPLICATION INFO.: US 1999-272960 19990318 19990318 (9) APPLICATION INFO .: NUMBER DATE _____ PRIORITY INFORMATION: US 1998-78891P 19980320 (60) DOCUMENT TYPE: Utility GRANTED FILE SEGMENT: PRIMARY EXAMINER: Smith, Lynette R. F.
ASSISTANT EXAMINER: Portner, Ginny Allen
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP NUMBER OF CLAIMS: EXEMPLARY CLAIM: 3 Drawing Figure(s); 4 Drawing Page(s) NUMBER OF DRAWINGS: LINE COUNT: CAS INDEXING IS AVAILABLE FOR THIS PATENT. The structure and specificity of a recombinant .alpha. 2,3-sialyltransferase from Campylobacter spp., is disclosed. Also provided are methods for using the . alpha.2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase. ANSWER 2 OF 37 USPATFULL on STN 2004:233335 USPATFULL ACCESSION NUMBER: Nucleic acids encoding sialytransferases from C. TITLE: Gilbert, Michel, Hull, CANADA INVENTOR(S): Wakarchuk, Warren W., Gloucester, CANADA National Research Council of Canada, Ottawa, CANADA PATENT ASSIGNEE(S): (non-U.S. corporation) KIND DATE NUMBER US 2004180406 A1 20040916 US 2003-735419 A1 20031211 (10) PATENT INFORMATION: APPLICATION INFO.: Continuation of Ser. No. US 2001-816028, filed on 21 RELATED APPLN. INFO.: Mar 2001, GRANTED, Pat. No. US 6699705 Continuation-in-part of Ser. No. US 2000-495406, filed on 31 Jan 2000, GRANTED, Pat. No. US 6503744 DATE NUMBER _____ US 1999-118213P 19990201 (60) PRIORITY INFORMATION: Utility DOCUMENT TYPE: APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE:

NUMBER OF DRAWINGS:

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 42

4 Drawing Page(s)

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

5466 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an $\alpha 2,3$ - and an α 2,8-activity. A β 1,4-GalNAc transferase and a β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host

ANSWER 3 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2004:202948 USPATFULL

TITLE:

Haemophilus influenzae sialyltransferase and methods of

use thereof

cells for expressing the glycosyltransferases.

INVENTOR(S):

Apicella, Michael A., Solon, IA, UNITED STATES Gibson, Bradford W., Berkeley, CA, UNITED STATES Phillips, Nancy J., Berkeley, CA, UNITED STATES Jones, Paul A., Coralville, IA, UNITED STATES

KIND DATE NUMBER -----US 2004156837 A1 20040812 PATENT INFORMATION: APPLICATION INFO.: US 2003-366548 A1 20030212 (10)

DOCUMENT TYPE:

Utility APPLICATION

FILE SEGMENT:

LEGAL REPRESENTATIVE: Schwegman, Lundberg, Woessner & Kluth, P.A., P.O. Box

2938, Minneapolis, MN, 55402

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

4 Drawing Page(s)

LINE COUNT:

2265

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention is directed to sialytransferases, such as SiaA sialytransferases isolated from Haemophilus influenzae. Further provided herein are methods for producing sialylated lipooligosaccharides, vaccines, and host cells and systems for the production of sialylated lipooligosaccharides.

ANSWER 4 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2004:196860 USPATFULL

TITLE:

Lipopolysaccharide alpha -2,

3 sialyltransferase of campylobacter

jejuni and its uses

INVENTOR(S):

Gilbert, Michel, Hull, CANADA

Wakarchuk, Warren W., Glouchester, CANADA

PATENT ASSIGNEE(S):

National Research Council of Canada, Ottawa, CANADA

(non-U.S. corporation)

NUMBER KIND DATE US 2004152165 Al 20040805 US 2004-799016 Al 20040311 (10) PATENT INFORMATION: APPLICATION INFO .:

RELATED APPLN. INFO.:

Division of Ser. No. US 2002-58636, filed on 29 Jan 2002, GRANTED, Pat. No. US 6709834 Division of Ser. No. US 1999-272960, filed on 18 Mar 1999, GRANTED, Pat. No.

US 6689604

NUMBER DATE _____

PRIORITY INFORMATION:

US 1998-78891P 19980320 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

4 Drawing Page(s)

1545

LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB

The structure and specificity of a recombinant .alpha.

2,3-sialyltransferase from Campylobacter

spp., is disclosed. Also provided are methods for using the .

alpha.2,3-sialyltransferase in the

production of desired carbohydrate structures and nucleic acids that

encode the sialyltransferase.

ANSWER 5 OF 37 USPATFULL on STN

2004:184970 USPATFULL

ACCESSION NUMBER: TITLE:

Glycoconjugation methods and proteins/peptides produced

by the methods

INVENTOR(S):

DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Bowe, Caryn, Doylestown, PA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc. (U.S. corporation)

NUMBER	KIND	DATE	

PATENT INFORMATION:

US 2004142856

A120040722

APPLICATION INFO .: RELATED APPLN. INFO.:

20030409 (10) US 2003-410913 **A1**

Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING

Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO

2002-US32263, filed on 9 Oct 2002, PENDING

NUMBER	DATE
 _	

PRIORITY INFORMATION:

US 2002-407527P 20020828 (60) 20020828 (60) US 2002-407527P 20020816 (60) US 2002-404249P 20020717 (60) US 2002-396594P 20020625 (60) US 2002-391777P 20020607 (60) US 2002-387292P 20011128 (60) US 2001-334301P 20011128 (60) US 2001-334233P 20011121 (60) US 2001-334692P 20011010 (60) US 2001-328523P

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

497 Drawing Page(s)

NUMBER OF DRAWINGS: LINE COUNT:

16544

88

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

```
ANSWER 6 OF 37 USPATFULL on STN
L3
                        2004:178391 USPATFULL
ACCESSION NUMBER:
                         Remodeling and glycoconjugation of peptides
TITLE:
                         DeFrees, Shawn, North Wales, PA, UNITED STATES
INVENTOR(S):
                         Zopf, David, Wayne, PA, UNITED STATES
                         Bayer, Robert, San Diego, CA, UNITED STATES
                         Bowe, Caryn, Doylestown, PA, UNITED STATES
                         Hakes, David, Willow Grove, PA, UNITED STATES
                         Chen, Xi, Lansdale, PA, UNITED STATES
                         Neose Technologies, Inc. (U.S. corporation)
PATENT ASSIGNEE(S):
                                          KIND DATE
                              NUMBER
                         -----
PATENT INFORMATION: US 2004137557 A1 20040715
APPLICATION INFO.: US 2002-287994 A1 20021105 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2002-US32263, filed on 9
                        Oct 2002, PENDING
                                          DATE
                               NUMBER
                         ______
PRIORITY INFORMATION: US 2002-407527P 20020828 (60)
US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
US 2002-391777P 20020625 (60)
US 2002-387292P 20020607 (60)
US 2001-334301P 20011128 (60)
US 2001-334233P 20011128 (60)
                Utility
APPLICATION
                        Utility
DOCUMENT TYPE:
FILE SEGMENT:
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,
                        PHILADELPHIA, PA, 19103-2921
                       447
NUMBER OF CLAIMS:
                        1
EXEMPLARY CLAIM:
                       345 Drawing Page(s)
NUMBER OF DRAWINGS:
                      16205
LINE COUNT:
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       The invention includes methods and compositions for remodeling a peptide
AB
       molecule, including the addition or deletion of one or more glycosyl
       groups to a peptide, and/or the addition of a modifying group a peptide.
     ANSWER 7 OF 37 USPATFULL on STN
                         2004:172476 USPATFULL
ACCESSION NUMBER:
                         Glycopegylation methods and proteins/peptides produced
TITLE:
                         by the methods
                         DeFrees, Shawn, North Wales, PA, UNITED STATES
INVENTOR(S):
                         Zopf, David, Wayne, PA, UNITED STATES
                         Bayer, Robert, San Diego, CA, UNITED STATES
                         Bowe, Caryn, Doylestown, PA, UNITED STATES
                         Hakes, David, Willow Grove, PA, UNITED STATES
                          Chen, Xi, Lansdale, PA, UNITED STATES
                         Neose Technologies, Inc. (U.S. corporation)
PATENT ASSIGNEE(S):
                             NUMBER KIND DATE
                          US 2004132640 A1 20040708
US 2003-411012 A1 20030409 (10)
PATENT INFORMATION:
APPLICATION INFO.:
                         Continuation-in-part of Ser. No. WO 2002-US32263, filed
RELATED APPLN. INFO.:
                          on 9 Oct 2002, PENDING
                                 NUMBER
                                              DATE
                          _______
                         US 2002-407527P 20020828 (60)
 PRIORITY INFORMATION:
                         US 2002-404249P 20020816 (60)
US 2002-396594P 20020717 (60)
```

US 2002-391777P 20020625 (60) US 2002-387292P 20020607 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 77 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 497 Drawing Page(s)

LINE COUNT: 19255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a

peptide.

L3 ANSWER 8 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2004:165351 USPATFULL

TITLE: Follicle stimulating hormone: remodeling and

glycoconjugation of FSH

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Bowe, Caryn, Doylestown, PA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser.

No. US 2003-360770, filed on 6 Jan 2003, PENDING

Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO

2002-US32263, filed on 9 Oct 2002, PENDING

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 115 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 497 Drawing Page(s)

LINE COUNT: 19355

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

peptide.

L3 ANSWER 9 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2004:150947 USPATFULL

TITLE: Interferon beta: remodeling and glycoconjugation of

interferon beta

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Bowe, Caryn, Doylestown, PA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 2004115168 A1 20040617

APPLICATION INFO.: US 2003-410930 A1 20030409 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING

Continuation-in-part of Ser. No. US 2002-287994, filed

on 5 Nov 2002, PENDING Continuation of Ser. No. WO

2002-US32263, filed on 9 Oct 2002, PENDING

NUMBER DATE ______ US 2002-407527P 20020828 (60) PRIORITY INFORMATION: 20020816 (60) US 2002-404249P 20020717 (60) US 2002-396594P 20020625 (60) US 2002-391777P 20020607 (60) US 2002-387292P 20011128 (60) US 2001-334301P 20011128 (60) US 2001-334233P 20011019 (60) US 2001-344692P 20011010 (60) US 2001-328523P

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 119 EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 497 Drawing Page(s)

LINE COUNT: 19412

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a

peptide.

L3 ANSWER 10 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2004:107626 USPATFULL

TITLE:

Interferon alpha: remodeling and glycoconjugation of

interferon alpha

INVENTOR (S):

DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Bowe, Caryn, Doylestown, PA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc. (U.S. corporation)

•		NUMBER	KIND	DATE	
DATENIT INFORMATION.		2004082026	71	20040420	
PATENT INFORMATION:		2004082026		20040429	(= 0)
APPLICATION INFO.:	US	2003-411049	A1	20030409	(10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser.

No. US 2003-360770, filed on 6 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO 2002-US32263, filed on 9 Oct 2002, PENDING

	2002-US32263, filed on 9 Oct 2002, PENDING
	NUMBER DATE
PRIORITY INFORMATION:	US 2002-407527P 20020828 (60)
PRIORITI INFORMATION:	US 2002-404249P 20020816 (60)
	US 2002-396594P 20020717 (60)
	US 2002-391777P 20020625 (60)
	US 2002-387292P 20020607 (60)
	US 2001-334301P 20011128 (60)
	US 2001-334233P 20011128 (60)
	US 2001-344692P 20011019 (60)
	US 2001-328523P 20011010 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921
NUMBER OF CLAIMS:	126
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	497 Drawing Page(s)
LINE COUNT:	19445
CAS INDEXING IS AVAILAB	LE FOR THIS PATENT.
AB The invention in	cludes a multitude of methods and compositions for
remodeling a pep	tide molecule, including the addition or deletion of one
	groups to a peptide, and/or the addition of a modifying
group to a pepti	de.
L3 ANSWER 11 OF 37 U	SPATFULL on STN 2004:101966 USPATFULL
TITLE:	Granulocyte colony stimulating factor: remodeling and
	glycoconjugation of G-CSF
INVENTOR(S):	DeFrees, Shawn, North Wales, PA, UNITED STATES
·	Zopf, David, Wayne, PA, UNITED STATES
	Bayer, Robert, San Diego, CA, UNITED STATES
	Bowe, Caryn, Doylestown, PA, UNITED STATES
	Hakes, David, Willow Grove, PA, UNITED STATES
	Chen, Xi, Lansdale, PA, UNITED STATES
PATENT ASSIGNEE(S):	Neose Technologies, Inc. (U.S. corporation)
	NUMBER WIND DATE
	NUMBER KIND DATE
PATENT INFORMATION:	US 2004077836 A1 20040422
APPLICATION INFO::	US 2003-410962 A1 20030409 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-360779, filed
RELATED ATTEN. INTO	on 19 Feb 2003, PENDING Continuation-in-part of Ser.
	No. US 2003-360770, filed on 6 Jan 2003, PENDING
	Continuation-in-part of Ser. No. US 2002-287994, filed
	on 5 Nov 2002, PENDING Continuation of Ser. No. WO
	2002-US32263, filed on 9 Oct 2002, PENDING
	·
	NUMBER DATE
PRIORITY INFORMATION:	US 2002-407527P 20020828 (60)
EXICKLI INFORMATION:	US 2002-404249P 20020816 (60)
	US 2002-404249P 20020816 (60) US 2002-396594P 20020717 (60)
	US 2002-396394P 20020717 (80) US 2002-391777P 20020625 (60)
	05 2002-39111F 20020023 (00) ,

			NUMBER	DATE	
PRIORITY	INFORMATION:	US	2002-407527P	20020828	(60)
		US	2002-404249P	20020816	(60)
		US	2002-396594P	20020717	(60)
		US	2002-391777P	20020625	(60)
		US	2002-387292P	20020607	(60)
		US	2001-334301P	20011128	(60)
		US	2001-334233P	20011128	(60)
	,	US	2001-344692P	20011019	(60)
		US	2001-328523P	20011010	(60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS:

111

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

497 Drawing Page(s)

LINE COUNT:

19316

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a

peptide.

ANSWER 12 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2004:83455 USPATFULL

TITLE:

Protein remodeling methods and proteins/peptides

produced by the methods

INVENTOR(S):

DeFrees, Shawn, North Wales, PA, UNITED STATES

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc. (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:

US 2004063911 A1 20040401

APPLICATION INFO.: RELATED APPLN. INFO.: US 2003-411026 A1 20030409 (10)

Continuation-in-part of Ser. No. US 2003-360779, filed on 19 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2003-360770, filed on 6 Jan 2003, PENDING

Continuation-in-part of Ser. No. US 2002-287994, filed on 5 Nov 2002, PENDING Continuation of Ser. No. WO

2002-US32263, filed on 9 Oct 2002, PENDING

NUMBER DATE

PRIORITY INFORMATION:

US 2002-407527P 20020828 (60) US 2002-404249P 20020816 (60) US 2002-396594P 20020717 (60) US 2002-391777P 20020625 (60) US 2002-387292P 20020607 (60) US 2001-334301P 20011128 (60) US 2001-334233P 20011128 (60) US 2001-344692P 20011019 (60) US 2001-328523P 20011010 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

497 Drawing Page(s)

NUMBER OF DRAWINGS: LINE COUNT:

18872

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

ANSWER 13 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2004:57444 USPATFULL

TITLE:

Alpha galalctosidase a: remodeling and glycoconjugation

of alpha galactosidase A

DeFrees, Shawn, North Wales, PA, UNITED STATES INVENTOR (S):

Zopf, David, Wayne, PA, UNITED STATES

Bayer, Robert, San Diego, CA, UNITED STATES Bowe, Caryn, Doylestown, PA, UNITED STATES Hakes, David, Willow Grove, PA, UNITED STATES

Chen, Xi, Lansdale, PA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc. (U.S. corporation)

NUMBER KIND DATE PATENT INFORMATION:

US 2004043446 A1 20040304 US 2003-411037 A1 20030409 (10)

APPLICATION INFO.: RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2002-US32263, filed

on 9 Oct 2002, PENDING

DATE NUMBER US 2002-407527P 20020828 (60) PRIORITY INFORMATION: US 2002-404249P 20020816 (60) US 2002-396594P 20020717 (60) US 2002-391777P 20020625 (60) US 2002-387292P 20020607 (60)

DOCUMENT TYPE:

Utility APPLICATION

FILE SEGMENT: LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET,

PHILADELPHIA, PA, 19103-2921

122 NUMBER OF CLAIMS:

EXEMPLARY CLAIM: 1

497 Drawing Page(s) NUMBER OF DRAWINGS:

19395 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

ANSWER 14 OF 37 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

ACCESSION NUMBER: 2004:237501 BIOSIS DOCUMENT NUMBER: PREV200400237395

TITLE:

Lipopolysaccharide alpha-2,3 sialytransferase of

campylobacter jejuni and its uses.

AUTHOR(S):

Gilbert, Michel [Inventor, Reprint Author]; Wakarchuk,

Warren W. [Inventor]

CORPORATE SOURCE:

Ouebec, Canada

ASSIGNEE: National Research Council of Canada, Ottawa,

Canada

PATENT INFORMATION: US 6709834 March 23, 2004

SOURCE:

Official Gazette of the United States Patent and Trademark

Office Patents, (Mar 23 2004) Vol. 1280, No. 4. http://www.uspto.gov/web/menu/patdata.html. e-file.

ISSN: 0098-1133 (ISSN print).

DOCUMENT TYPE:

Patent

LANGUAGE:

English

ENTRY DATE:

Entered STN: 28 Apr 2004

Last Updated on STN: 28 Apr 2004

The structure and specificity of a recombinant alpha2,3-sialyltransferase AB from Campylobacter spp., is disclosed. Also provided are methods for using the alpha2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase.

ACCESSION NUMBER:

2004:106956 CAPLUS

DOCUMENT NUMBER:

140:316978

TITLE:

Structural analysis of the sialyltransferase CstII

from Campylobacter jejuni in complex with a

substrate analog

AUTHOR (S):

Chiu, Cecilia P. C.; Watts, Andrew G.; Lairson, Luke L.; Gilbert, Michel; Lim, Daniel; Wakarchuk, Warren W.; Withers, Stephen G.; Strynadka, Natalie C. J.

CORPORATE SOURCE:

Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, V6T

1Z3, Can.

SOURCE:

Nature Structural & Molecular Biology (2004), 11(2),

163-170

CODEN: NSMBCU; ISSN: 1545-9993

PUBLISHER:

Nature Publishing Group

DOCUMENT TYPE:

Journal English

LANGUAGE:

Sialic acid terminates oligosaccharide chains on mammalian and microbial cell surfaces, playing critical roles in recognition and adherence. The enzymes that transfer the sialic acid moiety from cytidine-5'-monophospho-N-acetyl-neuraminic acid (CMP-NeuAc) to the terminal positions of these key glycoconjugates are known as sialyltransferases. Despite their important biol. roles, little is understood about the mechanism or mol. structure of these membrane-associated enzymes. We report the first structure of a sialyltransferase, that of CstII from Campylobacter jejuni, a highly prevalent foodborne pathogen. Our structural, mutagenesis and kinetic data provide support for a novel mode of substrate binding and glycosyl transfer mechanism, including essential roles of a histidine (general base) and two tyrosine residues (coordination of the phosphate leaving group). This work provides a framework for understanding the activity of several sialyltransferases, from bacterial to human, and for the structure-based design of specific inhibitors.

REFERENCE COUNT:

THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 16 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2003:257784 USPATFULL

TITLE:

In vitro modification of glycosylation patterns of

recombinant glycopeptides

INVENTOR(S):

Bayer, Robert J., San Diego, CA, UNITED STATES Neose Technologies, Inc., Horsham, PA (U.S.

corporation)

53

NUMBER DATE KIND

PATENT INFORMATION:

PATENT ASSIGNEE(S):

US 2003180835 A1 20030925 US 2003-391035 A1 20030317

APPLICATION INFO.:

(10)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 2001-855320, filed on 14

May 2001, PENDING

NUMBER DATE

PRIORITY INFORMATION:

-----US 2000-203851P 20000512 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

55

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

5 Drawing Page(s)

LINE COUNT:

2077

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also

provided are glycopeptide compositions in which the glycopeptides have a uniform glycosylation pattern.

ANSWER 17 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2003:225846 USPATFULL

TITLE:

Polypeptides having beta-1,4-GalNAc transferase

activity

INVENTOR(S):

Gilbert, Michel, Hull, CANADA

Wakarchuk, Warren W., Gloucester, CANADA

PATENT ASSIGNEE(S):

National Research Council of Canada, Ottawa, CANADA,

K1A OR6 (non-U.S. corporation)

NUMBER KIND DATE _____ US 2003157658 A1 20030821 PATENT INFORMATION: US 6723545 B2 20040420 US 2002-303162 B2 20040420 US 2002-303162 A1 20021121 (10) APPLICATION INFO.:

RELATED APPLN. INFO.:

Division of Ser. No. US 2001-816028, filed on 21 Mar 2001, PENDING Continuation-in-part of Ser. No. US

2000-495406, filed on 31 Jan 2000, GRANTED, Pat. No. US

6503744

NUMBER DATE

PRIORITY INFORMATION:

US 1999-118213P 19990201 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

4 Drawing Page(s)

LINE COUNT:

5466

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a AΒ bifunctional sialyltransferase that has both an $\alpha 2,3$ - and an $\alpha 2,8\text{-activity}.$ A $\beta 1,4\text{-GalNAc}$ transferase and a β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

ANSWER 18 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2003:225845 USPATFULL

TITLE:

Polypeptides having beta-1,3-galactosyl transferase

activity

INVENTOR(S):

Gilbert, Michel, Hull, CANADA

Wakarchuk, Warren W., Gloucester, CANADA

PATENT ASSIGNEE(S):

National Research Council of Canada, Ottawa, CANADA

(non-U.S. corporation)

NUMBER

NUMBER KIND DATE PATENT INFORMATION:

APPLICATION INFO .:

US 2003157657 A1 20030821 US 2002-303134 A1 20021121 (10)

RELATED APPLN. INFO.:

Division of Ser. No. US 2001-816028, filed on 21 Mar 2001, PENDING Continuation-in-part of Ser. No. US

2000-495406, filed on 31 Jan 2000, GRANTED, Pat. No. US

6503744

DATE

US 1999-118213P 19990201 (60) PRIORITY INFORMATION:

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

4 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 5460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a

bifunctional sialyltransferase that has both an $\alpha 2\,,3\,\text{-}$ and an

 α 2,8-activity. A β 1,4-GalNAc transferase and a

 β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni.

In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host

cells for expressing the glycosyltransferases.

ANSWER 19 OF 37 USPATFULL on STN

2003:225844 USPATFULL ACCESSION NUMBER:

Nucleic acids encoding beta-1,4-GaINAc transferase TITLE:

INVENTOR(S): Gilbert, Michel, Hull, CANADA

Wakarchuk, Warren W., Gloucester, CANADA

National Research Council of Canada, Ottawa, CANADA PATENT ASSIGNEE(S):

(non-U.S. corporation)

NUMBER KIND DATE

US 2003157656 A1 20030821 US 2002-303128 A1 20021121 (10) PATENT INFORMATION: APPLICATION INFO .:

RELATED APPLN. INFO.: Division of Ser. No. US 2001-816028, filed on 21 Mar 2001, PENDING Continuation-in-part of Ser. No. US

2000-495406, filed on 31 Jan 2000, GRANTED, Pat. No. US

6503744

NUMBER DATE ______

PRIORITY INFORMATION: US 1999-118213P 19990201 (60)

Utility DOCUMENT TYPE: FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

5474 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a

bifunctional sialyltransferase that has both an $\alpha 2,3$ - and an

 α 2,8-activity. A β 1,4-GalNAc transferase and a

 β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS), The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that

encode the glycosyltransferases, as well as expression vectors and host

cells for expressing the glycosyltransferases.

ANSWER 20 OF 37 USPATFULL on STN

2003:225843 USPATFULL ACCESSION NUMBER:

TITLE:

Nucleic acids encoding polypeptides with beta-1,3-galactosyl transferase activity

INVENTOR(S):

Gilbert, Michel, Hull, CANADA

Wakarchuk, Warren W., Gloucester, CANADA

PATENT ASSIGNEE(S):

National Research Council of Canada, Ottawa, CANADA, C

(non-U.S. corporation)

KIND DATE NUMBER

PATENT INFORMATION:

APPLICATION INFO.:

US 2003157655 A1 20030821 US 2002-303118 A1 20021121 (10)

RELATED APPLN. INFO.:

Division of Ser. No. US 2001-816028, filed on 21 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-495406, filed on 31 Jan 2000, GRANTED, Pat. No. US

6503744

NUMBER DATE

PRIORITY INFORMATION:

US 1999-118213P 19990201 (60)

DOCUMENT TYPE: FILE SEGMENT:

Utility APPLICATION .

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

4 Drawing Page(s)

LINE COUNT:

5465

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a AB bifunctional sialyltransferase that has both an $\alpha 2,3$ - and an

 $\alpha 2,8\text{-activity.}$ A $\beta 1,4\text{-GalNAc}$ transferase and a β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni.

In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

ANSWER 21 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2003:213821 USPATFULL

TITLE:

Polypeptides having sialyltransferase activity

INVENTOR (S):

Gilbert, Michel, Hull, CANADA

Wakarchuk, Warren W., Gloucester, CANADA

PATENT ASSIGNEE(S):

National Research Council of Canada, Ottawa, CANADA

(non-U.S. corporation)

KIND DATE NUMBER _____ US 2003148459 A1 20030807 US 2002-303161 A1 20021121 (10) PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.:

Division of Ser. No. US 2001-816028, filed on 21 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2000-495406, filed on 31 Jan 2000, GRANTED, Pat. No. US

6503744

NUMBER DATE

PRIORITY INFORMATION:

US 1999-118213P 19990201 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT: LEGAL REPRESENTATIVE:

APPLICATION TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

4 Drawing Page(s)

LINE COUNT:

5430

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a bifunctional sialyltransferase that has both an $\alpha 2,3$ - and an

 α 2,8-activity. A β 1,4-GalNAc transferase and a

 β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained

from, for example, Campylobacter species, including C. jejuni.

In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host

cells for expressing the glycosyltransferases.

ANSWER 22 OF 37 USPATFULL on STN L3

ACCESSION NUMBER:

2003:180815 USPATFULL

TITLE:

Practical in vitro sialylation of recombinant

glycoproteins

INVENTOR (S):

Paulson, James C., Del Mar, CA, UNITED STATES Bayer, Robert J., San Diego, CA, UNITED STATES Sjoberg, Eric, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc., Horsham, PA, UNITED STATES

(U.S. corporation)

KIND DATE NUMBER ______

PATENT INFORMATION:

US 2003124645 A1 20030703 US 2002-219120 A1 20020813 (10)

APPLICATION INFO.:

RELATED APPLN. INFO.:

Continuation of Ser. No. US 2001-7331, filed on 9 Nov 2001, PENDING Division of Ser. No. US 1998-7741, filed

on 15 Jan 1998, GRANTED, Pat. No. US 6399336

NUMBER DATE

PRIORITY INFORMATION:

WO 1998-US835 19980115 US 1997-35710P 19970116 (60)

DOCUMENT TYPE:

FILE SEGMENT:

Utility APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

58

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

2 Drawing Page(s)

LINE COUNT:

1146

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for practical in vitro sialylation of

glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.

ANSWER 23 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2003:70985 USPATFULL

TITLE:

Lipopolysaccharide alpha-2,

3 sialyltransferase of Campylobacter

jejuni and its uses

INVENTOR (S):

Gilbert, Michel, Quebec, CANADA

Wakarchuk, Warren W., Ontario, CANADA

PATENT ASSIGNEE(S):

National Research Council of Canada, Ottawa, CANADA

(non-U.S. corporation)

KIND DATE NUMBER _____ US 2003049270 A1 20030313 PATENT INFORMATION: US 6709834 B2 20040323

US 2002-58636 APPLICATION INFO .:

A1 20020129 (10)

RELATED APPLN. INFO.:

Division of Ser. No. US 1999-272960, filed on 18 Mar

1999, PENDING

NUMBER DATE

PRIORITY INFORMATION:

US 1998-78891P 19980320 (60)

Utility DOCUMENT TYPE:

APPLICATION FILE SEGMENT:

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

1

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

4 Drawing Page(s)

LINE COUNT:

1545

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The structure and specificity of a recombinant .alpha. 2,3-sialyltransferase from Campylobacter

spp., is disclosed. Also provided are methods for using the .

alpha.2,3-sialyltransferase in the

production of desired carbohydrate structures and nucleic acids that

encode the sialyltransferase.

ANSWER 24 OF 37 USPATFULL on STN L3

ACCESSION NUMBER:

2003:57473 USPATFULL

TITLE:

In vitro modification of glycosylation patterns of

recombinant glycopeptides

INVENTOR(S):

Bayer, Robert J., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc., Horsham, PA, UNITED STATES

(U.S. corporation)

NUMBER KIND DATE -----

PATENT INFORMATION:

US 2003040037

A1 20030227

APPLICATION INFO.:

US 2002-219197 A1 20020813 (10)

RELATED APPLN. INFO.:

Continuation of Ser. No. US 2001-855320, filed on 14

May 2001, PENDING

NUMBER DATE

PRIORITY INFORMATION:

WO 2001-US15693 20010514

20000512 (60)

DOCUMENT TYPE:

US 2000-203851P Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

5 Drawing Page(s)

LINE COUNT:

2071

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a

uniform glycosylation pattern.

ANSWER 25 OF 37 USPATFULL on STN

ACCESSION NUMBER: TITLE:

2003:3494 USPATFULL Vitro modification of glycosylation patterns of

recombinant glycopeptides

INVENTOR(S):

Bayer, Robert J., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc., Horsham, PA, UNITED STATES

(U.S. corporation)

NUMBER KIND DATE PATENT INFORMATION: US 2003003529 A1 20030102 APPLICATION INFO.: US 2002-198806 A1 20020719 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2001-855320, filed on 14 May

2001, PENDING

NUMBER DATE

PRIORITY INFORMATION:

WO 2001-US15693 20010514 US 2000-203851P 20000512 (60)

DOCUMENT TYPE: Utility APPLICATION FILE SEGMENT:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO LEGAL REPRESENTATIVE:

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: EXEMPLARY CLAIM: 1

5 Drawing Page(s) NUMBER OF DRAWINGS:

2076 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a uniform glycosylation pattern.

ANSWER 26 OF 37 USPATFULL on STN

2003:6819 USPATFULL ACCESSION NUMBER:

Campylobacter glycosyltransferases for biosynthesis of TITLE:

gangliosides and ganglioside mimics

Gilbert, Michel, Hull, CANADA INVENTOR(S):

Wakarchuk, Warren W., Gloucester, CANADA

National Research Council of Canada, Ottawa, CANADA PATENT ASSIGNEE(S):

(non-U.S. corporation)

NUMBER KIND DATE ______ US 6503744 B1 20030107 PATENT INFORMATION: APPLICATION INFO.:

US 2000-495406 20000131 (9)

NUMBER DATE

PRIORITY INFORMATION: US 1999-118213P 19990201 (60)

DOCUMENT TYPE: Utility GRANTED FILE SEGMENT:

PRIMARY EXAMINER: Prouty, Rebecca E. ASSISTANT EXAMINER: Rao, Manjunath N.

LEGAL REPRESENTATIVE: Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS: EXEMPLARY CLAIM:

7 Drawing Figure(s); 4 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 4086

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides prokaryotic glycosyltransferases, including a AB bifunctional sialyltransferase that has both an $\alpha 2\,,3\,\text{-}$ and an α 2,8-activity. A β 1,4-GalNAc transferase and a β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). The glycosyltransferases can be obtained from, for example, Campylobacter species, including C. jejuni. In additional embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases.

ANSWER 27 OF 37 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. L3

on STN

ACCESSION NUMBER:

2003:443221 SCISEARCH

THE GENUINE ARTICLE: 680EE

TITLE:

Large-scale in vivo synthesis of the carbohydrate moieties of gangliosides GM1 and GM2 by metabolically engineered

Escherichia coli

AUTHOR:

Antoine T (Reprint); Priem B; Heyraud A; Greffe L; Gilbert

M; Wakarchuk B W; Lam J S; Samain E

CORPORATE SOURCE:

Ctr Rech Macromol Vegetales, 601 Rue Chim, BP 53X, F-38041

Grenoble 09, France (Reprint); Ctr Rech Macromol

Vegetales, F-38041 Grenoble 09, France; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Univ

Guelph, Dept Microbiol, Guelph, ON N1G 2W1, Canada

COUNTRY OF AUTHOR:

France; Canada

SOURCE:

CHEMBIOCHEM, (9 MAY 2003) Vol. 4, No. 5, pp. 406-412. Publisher: WILEY-V C H VERLAG GMBH, PO BOX 10 11 61,

D-69451 WEINHEIM, GERMANY.

ISSN: 1439-4227.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT:

28

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS Two metabolically engineered Escherichia coli strains have been constructed to produce the carbohydrate moieties of gangliosides GM2 (GalNAcbeta-4 (NeuAcalpha-3) Galbeta-4Glc; Gal=galactose, Glc=glucose Ac=acetyl) and GM1 (Galbeta-3GalNAcbeta-4 (NeuAcalpha-3) Galbeta-4Glc. The GM2 oligosaccharide-producing strain TA02 Was devoid of both beta-galactosidase and sialic acid aldolase activities and overexpressed the genes for CMP-NeuAc Synthase (CMP = cytidine monophosphate),

alpha-2,3-sialyltransferase

UDP-GlcNAc (UDP=uridine diphosphate) C4 epimerase, and beta-1,4-GalNAc transferase. When this strain was cultivated on glycerol, exogenously added lactose and sialic acid were shown to be actively internalized into the cytoplasm and converted into GM2 oligosaccharide. The in vivo synthesis of GM1 oligosaccharide was achieved, by taking a similar approach but using strain TAGS, which additionally overexpressed the gene for beta-1,3-galactosyltransferase. In high-cell-density cultures, the production yields for the GM2 and GM1 oligosaccharides were 1.25 g L-1 and 0,89 g L-1, respectively.

ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER:

2002:276514 CAPLUS

DOCUMENT NUMBER:

136:320378

TITLE:

Campylobacter glycosyltransferase genes and enzymes for biosynthesis of gangliosides and ganglioside

INVENTOR(S):

Gilbert, Michel; Wakarchuk, Warren W.

PATENT ASSIGNEE(S):

National Research Council of Canada, Can.

SOURCE:

U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S.

Ser. No. 495,406.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
		-		
US 2002042369	A1	20020411	US 2001-816028	20010321
US 6699705	B2	20040302	•	
US 6503744	B1	20030107	US 2000-495406	20000131
WO 2002074942	A2	20020926	WO 2002-CA229	20020222
WO 2002074942	A3 [']	20030313		
WO 2002074942	B1	20030703		

```
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
             FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
             MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW,
             AM, AZ, BY,
                         KG
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                             EP 2002-703414
                                                                      20020222
                           A2
                                 20040204
     EP 1385941
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                                              JP 2002-574334
                                                                       20020222
                           T2
                                 20040812
     JP 2004524033
                                             US 2002-303161
                                                                      20021121
     US 2003148459
                           A1
                                 20030807
                                              US 2002-303118
                                                                      20021121
     US 2003157655
                           A1
                                 20030821
                                              US 2002-303128
                                                                      20021121
     US 2003157656
                           A1
                                 20030821
                                              US 2002-303134
                                                                      20021121
     US 2003157657
                           A1
                                 20030821
                                              US 2002-303162
                                                                      20021121
     US 2003157658
                           A1
                                 20030821
     US 6723545
                           B2
                                 20040420
                                              US 2003-735419
                                                                      20031211
                                 20040916
     US 2004180406
                          A1
                                              US 1999-118213P
                                                                   P 19990201
PRIORITY APPLN. INFO.:
                                              US 2000-495406
                                                                   A2 20000131
                                              US 2001-816028
                                                                   A 20010321
                                             WO 2002-CA229
                                                                   W 20020222
     This invention provides Campylobacter jejuni
```

AB glycosyltransferases, including a bifunctional sialyltransferase that has both an $\alpha 2,3$ - and an $\alpha 2,8$ -activity. A $\beta 1,4$ -GaINAc transferase and a β 1,3-galactosyltransferase are also provided by the invention, as are other glycosyltransferases and enzymes involved in synthesis of lipooligosaccharide (LOS). In addnl. embodiments, the invention provides nucleic acids that encode the glycosyltransferases, as well as expression vectors and host cells for expressing the glycosyltransferases. The enzymes may be used in preparation of gangliosides, lysogangliosides, and mimics of gangliosides and lysogangliosides. Thus, C. jejuni gene cstI .alpha.2,3sialyltransferase, gene cstII bifunctional $\alpha 2,3/\alpha 2,8$ sialyltransferase, gene cgtA β -1,4-N-acetylgalactosaminyltransferase, and gene cgtB β -1,3-galactosyltransferase enzymes were used to prepare the carbohydrate portion of gangliosides GM1a, GM2, GM3, GD1a, GD3, and GT1a.

L3 ANSWER 29 OF 37 USPATFULL on STN

ACCESSION NUMBER: 2002:287597 USPATFULL

TITLE: Practic

Practical in vitro sialylation of recombinant

glycoproteins

INVENTOR(S): Paulson, James C., Del Mar, CA, UNITED STATES

Bayer, Robert J., San Diego, CA, UNITED STATES

Sjoberg, Eric, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Inc., Horsham, PA (U.S.

corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002160460	A1	20021031	
APPLICATION INFO.:	US 2002-81456	A1	20020221 (10)	
RELATED APPLN. INFO.:	Continuation of	Ser. No	. US 1998-7741,	filed on 15 Jan
	1998, GRANTED, P	at. No.	US 6399336	

NUMBER DATE

PRIORITY INFORMATION: US 1997-35710P 19970116 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO LEGAL REPRESENTATIVE:

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS: 58

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

2 Drawing Page(s)

LINE COUNT:

1142

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The

methods are useful for large-scale modification of sialylation patterns.

ANSWER 30 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2002:258800 USPATFULL

TITLE:

Practical in vitro sialylation of recombinant

glycoproteins

INVENTOR(S):

Paulson, James C., Del Mar, CA, UNITED STATES Bayer, Robert J., San Diego, CA, UNITED STATES Sjoberg, Eric, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S):

Neose Technologies, Inc., Horsham, PA, UNITED STATES,

19044 (U.S. corporation)

KIND DATE NUMBER

PATENT INFORMATION: US 2002142370 A1 20021003 APPLICATION INFO.: US 2002-81455 A1 20020221 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-7741, filed on 15 Jan

1998, GRANTED, Pat. No. US 6399336

NUMBER DATE _____

PRIORITY INFORMATION:

US 1997-35710P 19970116 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

NUMBER OF DRAWINGS:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

58 1

EXEMPLARY CLAIM:

2 Drawing Page(s)

LINE COUNT:

1135

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for practical in vitro sialylation of AR glycoproteins, including recombinantly produced glycoproteins. The

methods are useful for large-scale modification of sialylation patterns.

ANSWER 31 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2002:221376 USPATFULL

TITLE:

Practical in vitro sialylation of recombinant

glycoproteins

INVENTOR(S):

Paulson, James C., Del Mar, CA, UNITED STATES Bayer, Robert J., San Diego, CA, UNITED STATES Sjoberg, Eric, San Diego, CA, UNITED STATES

Cytel Corporation (U.S. corporation) PATENT ASSIGNEE(S):

> KIND DATE NUMBER ______ US 2002119516 A1 20020829 US 2001-7331 A1 20011109 (10)

PATENT INFORMATION: APPLICATION INFO.:

RELATED APPLN. INFO.:

Division of Ser. No. US 1998-7741, filed on 15 Jan

1998, PENDING

NUMBER DATE _____

PRIORITY INFORMATION:

US 1997-35710P 19970116 (60)

DOCUMENT TYPE:

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS: 1 2 Drawing Page(s)

LINE COUNT:

1150

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The

methods are useful for large-scale modification of sialylation patterns.

ANSWER 32 OF 37 USPATFULL on STN L3

ACCESSION NUMBER:

2002:32520 USPATFULL

TITLE:

In vitro modification of glycosylation patterns of

recombinant glycopeptides

INVENTOR(S):

Bayer, Robert, San Diego, CA, UNITED STATES

NUMBER KIND DATE

PATENT INFORMATION: APPLICATION INFO.:

US 2002019342 A1 20020214 US 2001-855320 A1 20010514 (9)

NUMBER DATE

PRIORITY INFORMATION:

US 2000-203851P 20000512 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

TOWNSEND AND TOWNSEND AND CREW, TWO EMBARCADERO CENTER,

EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834

NUMBER OF CLAIMS:

EXEMPLARY CLAIM: NUMBER OF DRAWINGS:

5 Drawing Page(s)

LINE COUNT:

2069

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for modifying glycosylation patterns of glycopeptides, including recombinantly produced glycopeptides. Also provided are glycopeptide compositions in which the glycopeptides have a uniform glycosylation pattern.

ANSWER 33 OF 37 USPATFULL on STN

ACCESSION NUMBER:

2002:129751 USPATFULL

TITLE:

Practical in vitro sialylation of recombinant

glycoproteins

INVENTOR(S):

Paulson, James C., Del Mar, CA, United States Bayer, Robert J., San Diego, CA, United States Sjoberg, Eric, San Diego, CA, United States

PATENT ASSIGNEE(S):

Neose Technologies, Inc., Horsham, PA, United States

(U.S. corporation)

KIND DATE ______ US 6399336 B1 20020604 PATENT INFORMATION: 19980115 (9) US 1998-7741 APPLICATION INFO.:

> NUMBER DATE _____

PRIORITY INFORMATION:

US 1997-35710P 19970116 (60)

DOCUMENT TYPE:

Utility GRANTED

FILE SEGMENT: PRIMARY EXAMINER:

Achutamurthy, Ponnathapu

ASSISTANT EXAMINER:

Rao, Manjunath N.

LEGAL REPRESENTATIVE:

Townsend and Townsend and Crew LLP

NUMBER OF CLAIMS:

EXEMPLARY CLAIM:

NUMBER OF DRAWINGS:

2 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT:

1239

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.

ANSWER 34 OF 37 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. L3

on STN

2001:339631 SCISEARCH. ACCESSION NUMBER:

THE GENUINE ARTICLE: 423VN

Dependence of the bi-functional nature of a TITLE:

sialyltransferase from Neisseria meningitidis on a single

amino acid substitution

Wakarchuk W W (Reprint); Watson D; St Michael F; Li J J; **AUTHOR:**

Wu Y Y; Brisson J R; Young N M; Gilbert M

Natl Res Council Canada, Inst Biol Sci, Immunochem CORPORATE SOURCE:

Program, 100 Sussex Dr, Ottawa, ON K1A OR6, Canada (Reprint); Natl Res Council Canada, Inst Biol Sci, Immunochem Program, Ottawa, ON K1A OR6, Canada

COUNTRY OF AUTHOR:

Canada

SOURCE:

JOURNAL OF BIOLOGICAL CHEMISTRY, (20 APR 2001) Vol. 276,

No. 16, pp. 12785-12790.

Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC,

9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA.

ISSN: 0021-9258.

DOCUMENT TYPE:

Article; Journal

LANGUAGE:

English

REFERENCE COUNT: 27

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

The L1 immunotype strain 126E of Neisseria meningitidis has been shown to have an N-acetyl-neuraminic acid-containing lipooligosaccharide in which an alpha -linked galactose from a pk epitope is substituted at the O6 position (Wakarchuk, W, W,, Gilbert, M,, Martin, A., Wu, Y,, Brisson, J, R,, Thibault, P,, and Richards, J, C, (1998) Eur. J, Biochem. 254, 626-633), Using a synthetic pk-epitope containing acceptor in glycosyltransferase reactions, we were able to show by NMR analysis of the reaction product that the 126E(L1) -derived sialyltransferase can make both alpha -2,3 and alpha -2,6 linkages to the terminal galactose, Gene disruption experiments showed that the Ist gene in 126E(L1) was responsible for the in vivo addition of the alpha -2,6-linked N-acetyl-neuraminic acid residue. By site-directed mutagenesis it was possible to change the MC58(L3)-derived enzyme into a bifunctional enzyme with a single amino acid change at position 168, where a glycine was changed to an isoleucine. We performed a gene replacement experiment where the 126E(L1) alpha -2,3/6-sialyltransferase was replaced by allelic exchange with the monofunctional MC58(L3) alpha -2, 3-sialyltransferase and with the mutant MC58(L3) allele G168I, We observed that the level of LOS sialylation with the G168I allele was very similar to that of the wild type 126E(L1), indicating that residue 168 is the critical residue for the alpha -2,6-sialyltransferase activity in vitro as well as in vivo.

ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3 L3

ACCESSION NUMBER:

2000:129311 CAPLUS

DOCUMENT NUMBER:

132:304980

TITLE:

Biosynthesis of ganglioside mimics in Campylobacter

jejuni OH4384. Identification of the

glycosyltransferase genes, enzymatic synthesis of model compounds, and characterization of nanomole

amounts by 600-MHz H and C NMR analysis

AUTHOR(S):

Gilbert, Michel; Brisson, Jean-Robert; Karwaski, Marie-France; Michniewicz, Joseph; Cunningham,

Anna-Maria; Wu, Yuyang; Young, N. Martin; Wakarchuk,

Warren W.

CORPORATE SOURCE: Institute for Biological Sciences, National Research

> Council of Canada, Ottawa, ON, K1A OR6, Can. Journal of Biological Chemistry (2000), 275(6),

3896-3906

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal

SOURCE:

LANGUAGE: English

We have applied two strategies for the cloning of four genes responsible for the biosynthesis of the GT1a ganglioside mimic in the

lipooligosaccharide (LOS) of a bacterial pathogen, Campylobacter jejuni OH4384, which has been associated with Guillain-Barre

syndrome. We first cloned a gene encoding an .alpha.-2

,3-sialyltransferase (cst-I) using an activity

screening strategy. We then used nucleotide sequence information from the recently completed sequence from C. jejuni NCTC 11168 to amplify

a region involved in LOS biosynthesis from C. jejuni OH4384. The LOS biosynthesis locus from C. jejuni OH4384 is 11.47

kilobase pairs and encodes 13 partial or complete open reading frames,

while the corresponding locus in C. jejuni NCTC 11168 spans

13.49 kilobase pairs and contains 15 open reading frames, indicating a different organization between these two strains. Potential

glycosyltransferase genes were cloned individually, expressed in Escherichia coli, and assayed using synthetic fluorescent oligosaccharides

as acceptors. We identified genes encoding a β -1,4-N-

acetylgalactosaminyltransferase (cgtA), a β -1,3-galactosyltransferase (cgtB), and a bifunctional sialyltransferase (cst-II), which transfers sialic acid to 0-3 of galactose and to 0-8 of a sialic acid that is linked α -2,3- to a galactose. The linkage specificity of each identified glycosyltransferase was confirmed by NMR anal. at 600 MHz on nanomole amts. of model compds. synthesized in vitro. Using a gradient inverse

broadband nano-NMR probe, sequence information could be obtained by detection of 3J(C,H) correlations across the glycosidic bond. The role of cgtA and cst-II in the synthesis of the GT1a mimic in C. jejuni

OH4384 were confirmed by comparing their sequence and activity with corresponding homologs in two related C. jejuni strains that express shorter ganglioside mimics in their LOS.

REFERENCE COUNT:

31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1999:626342 CAPLUS

DOCUMENT NUMBER:

131:253359

TITLE:

Campylobacter **jejuni** gene cst-I lipopolysaccharide .alpha.-2, 3 sialyltransferase, its DNA and

amino acid sequences, recombinant production, and its

acceptor specificity

INVENTOR(S):

Gilbert, Michel; Wakarchuk, Warren W. National Research Council of Canada, Can.

PATENT ASSIGNEE(S): SOURCE:

PCT Int. Appl., 47 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9949051	A1	19990930	WO 1999-CA238	19990322
W: AE, AL,	AM, AT, AU	, AZ, BA,	BB, BG, BR, BY, CA, CH,	CN. CH. CZ

```
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
             ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
             CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
                                             US 1999-272960
     US 6689604
                                 20040210
                                                                     19990318
                          B1
     CA 2323753
                                 19990930
                                             CA 1999-2323753
                                                                     19990322
                          AA
     AU 9928230
                                             AU 1999-28230
                                 19991018
                                                                     19990322
                          A1
     AU 745040
                           B2
                                 20020307
     EP 1082440
                                             EP 1999-908717
                          A1
                                 20010314
                                                                     19990322
            AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002507424
                          T2
                                             JP 2000-538012
                                 20020312
                                                                     19990322
     US 2003049270
                                             US 2002-58636
                          A1
                                 20030313
                                                                     20020129
     US 6709834
                          B2
                                 20040323
     US 2004152165
                                 20040805
                                             US 2004-799016
                          A1
                                                                     20040311
PRIORITY APPLN. INFO.:
                                             US 1998-78891P
                                                                 P 19980320
                                             US 1999-272960
                                                                    19990318
                                                                 Α
                                             WO 1999-CA238
                                                                    19990322
                                                                 W
                                             US 2002-58636
                                                                 A3 20020129
     The invention provides DNA mols. that encode gene cst-I lipopolysaccharide
AB
     .alpha.-2,3 sialyltransferase of
     Campylobacter jejuni. The DNA sequence of C. jejuni
     gene cst-I, as well as the corresponding amino acid sequence of
     lipopolysaccharide .alpha.-2,3
     sialyltransferase are claimed. The invention also provides
     methods for the recombinant production of lipopolysaccharide .alpha
     .-2,3 sialyltransferase in prokaryotic and
     eukaryotic cells. The invention further provides the specificity of the
     C. jejuni lipopolysaccharide .alpha.-2,
     3 sialyltransferase. The C. jejuni
     lipopolysaccharide .alpha.-2,3
     sialyltransferase uses terminal galactose acceptors that are
     \beta-(1\rightarrow4) linked to either glucose or N-acetylglucosamine. The
     enzyme also uses terminal galactose acceptors that are \beta-(1\rightarrow3)
     linked to N-acetylglucosamine or N-acetylgalactosamine. The enzyme uses
     cytidine monophosphate-N-acetylneuraminic acid (CMP-Neu5Ac) as the donor.
     The broad acceptor specificity of lipopolysaccharide .alpha. -
     2,3 sialyltransferase encoded by cst-I
     demonstrates its utility and makes it an attractive tool for chemo-enzymic
     synthesis of sialylated oligosaccharides.
REFERENCE COUNT:
                               THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 37 OF 37 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
     on STN
                                                         DUPLICATE 4
ACCESSION NUMBER:
                     1999:733349 SCISEARCH
THE GENUINE ARTICLE: 238JB
                     Synthesis of a disialylated hexasaccharide of Type VIII
TITLE:
                     Group B Streptococcus capsular polysaccharide
AUTHOR:
                     Eichler E; Jennings H J; Gilbert M; Whitfield D M
                     (Reprint)
CORPORATE SOURCE:
                     NATL RES COUNCIL CANADA, 100 SUSSEX DR, OTTAWA, ON K1A
                     OR6, CANADA (Reprint); NATL RES COUNCIL CANADA, OTTAWA, ON
                     K1A OR6, CANADA
COUNTRY OF AUTHOR:
                     CANADA
SOURCE:
                     CARBOHYDRATE RESEARCH, (30 JUN 1999) Vol. 319, No. 1-4,
```

Publisher: ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE,

KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND.

ISSN: 0008-6215.

DOCUMENT TYPE: FILE SEGMENT:

Article; Journal PHYS; LIFE; AGRI

LANGUAGE:

English

REFERENCE COUNT:

21

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS As part of our program to design, develop and prepare protective vaccines against the bacterial pathogens Group B Streptococcus, we report the synthesis of a disialylated hexasaccharide. This hexasaccharide represents a portion of the serotype-specific capsular polysaccharide of Type VIII that has the tetrasaccharide repeat unit {beta-L-Rhap-(1 --> 4) -beta-D-Glcp-(1 --> 4) - [alpha-Neu5Ac-(2 --> 3)] -beta-D-Galp-(1 --> 4) } (n). A tetrasaccharide corresponding to this repeat unit has been synthesized by us [E. Eichler, H.J. Jennings, D.M. Whitfield, J. Carbohydr. Chern., 16 (1997) 385-411]. Since the protective epitopes are believed to involve several. repeat units, methods to extend this tetrasaccharide were examined. This objective requires a glycosylation of the unreactive OH-4 of the beta-L-Rhap, which was accomplished by coupling a D-Galp glycosyl trichloroacetimidate donor with a beta-L-Rhap-(1 --> 4) -D-Glcp acceptor. Subsequent coupling of this trisaccharide as a donor to an a-Neu5Ac-(:2 --> 3)-D-Galp disaccharide acceptor gave a pentasaccharide. The pentasaccharide was deprotected and enzymatically sialylated using an alpha-(2 --> 3)sialyltransferase from Campylobacter jejuni to give the title hexasaccahride alpha-Neu5Ac-(2 --> 3)-beta-D-Galp-(1 --> 4)-beta-L-Rhap-(1 --> 4)-beta-D-Glcp(1 --> 4)-[alpha-Neu5Ac-(2 --> 3)]-beta-D-Galp-(1 --> 0)-(CH2)(3)N-3. (C) 1999 Elsevier Science Ltd. All rights reserved.